| Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma (NCT04852328) | Washington University School of Medicine | 2021-12-06 |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) (NCT04801472) | Institut de cancérologie Strasbourg Europe | 2021-05-07 |
| Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) (NCT04609280) | University of Maryland, Baltimore | 2021-03-01 |
| Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (NCT04718415) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-01-23 |
| Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer (NCT04572100) | University of Chicago | 2020-10-01 |
| Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma (NCT04220749) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2020-06-25 |
| Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging (NCT04222543) | Radboud University Medical Center | 2019-11-22 |
| Oropharynx (OPX) Biomarker Trial (NCT06356272) | Mayo Clinic | 2019-11-15 |
| De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (NCT03952585) | National Cancer Institute (NCI) | 2019-10-09 |
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy (NCT03611205) | Ohio State University Comprehensive Cancer Center | 2019-07-01 |
| Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer (NCT07407205) | Institute of Oncology Ljubljana | 2019-06-10 |
| A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse (NCT06138483) | Centro di Riferimento Oncologico - Aviano | 2019-04-19 |
| Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. (NCT03623646) | Institut Claudius Regaud | 2019-03-15 |
| Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma (NCT03618654) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-11-01 |
| Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC (NCT03410615) | Canadian Cancer Trials Group | 2018-05-28 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT03258554) | National Cancer Institute (NCI) | 2018-04-03 |
| Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (NCT02582008) | Wake Forest University Health Sciences | 2016-01-01 |
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma (NCT02156180) | Queensland Centre of Excellence for Head and Neck Cancer | 2014-04-01 |
| The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) (NCT02072148) | Icahn School of Medicine at Mount Sinai | 2014-03-01 |
| Efficacy and Safety of TORS for SCCA (NCT01819480) | Katherine L Fedder | 2013-03-01 |
| Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC (NCT01874171) | University of Warwick | 2012-11-15 |